PMID- 36874030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230307
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Dendrobium mixture ameliorates type 2 diabetes mellitus with non-alcoholic fatty 
      liver disease through PPAR gamma: An integrated study of bioinformatics analysis 
      and experimental verification.
PG  - 1112554
LID - 10.3389/fphar.2023.1112554 [doi]
LID - 1112554
AB  - Dendrobium mixture (DM) is a patented Chinese herbal medicine indicated which has 
      anti-inflammatory and improved glycolipid metabolism. However, its active 
      ingredients, targets of action, and potential mechanisms are still uncertain. 
      Here, we investigate the role of DM as a prospective modulator of protection 
      against non-alcoholic fatty liver disease (NAFLD) induced by type 2 diabetes 
      mellitus (T2DM) and illustrate the molecular mechanisms potentially involved. The 
      network pharmacology and TMT-based quantitative protomics analysis were conducted 
      to identify potential gene targets of the active ingredients in DM against NAFLD 
      and T2DM. DM was administered to the mice of DM group for 4 weeks, and db/m mice 
      (control group) and db/db mice (model group) were gavaged by normal saline. DM 
      was also given to Sprague-Dawley (SD) rats, and the serum was subjected to the 
      palmitic acid-induced HepG2 cells with abnormal lipid metabolism. The mechanism 
      of DM protection against T2DM-NAFLD is to improve liver function and pathological 
      morphology by promoting peroxisome proliferator-activated receptor gamma (PPARgamma) 
      activation, lowering blood glucose, improving insulin resistance (IR), and 
      reducing inflammatory factors. In db/db mice, DM reduced RBG, body weight, and 
      serum lipids levels, and significantly alleviated histological damage of liver 
      steatosis and inflammation. It upregulated the PPARgamma corresponding to the 
      prediction from the bioinformatics analysis. DM significantly reduced 
      inflammation by activating PPARgamma in both db/db mice and palmitic acid-induced 
      HepG2 cells.
CI  - Copyright (c) 2023 Zhuang, Zhang, Lin, Wang, Yu and Shi.
FAU - Zhuang, Shuting
AU  - Zhuang S
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
FAU - Zhang, Jieping
AU  - Zhang J
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
FAU - Lin, Xiaohui
AU  - Lin X
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
FAU - Wang, Xiaoning
AU  - Wang X
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
FAU - Yu, Wenzhen
AU  - Yu W
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
FAU - Shi, Hong
AU  - Shi H
AD  - College of Integrated Traditional Chinese and Western Medicine, Fujian University 
      of Traditional Chinese Medicine, Fuzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230216
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9978952
OTO - NOTNLM
OT  - PPAR gamma
OT  - TMT-based quantitative protomics
OT  - dendrobium mixture
OT  - inflammation
OT  - network pharmacology
OT  - non-alcoholic fatty liver disease
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/07 06:00
MHDA- 2023/03/07 06:01
PMCR- 2023/02/16
CRDT- 2023/03/06 03:49
PHST- 2022/11/30 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/03/06 03:49 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/07 06:01 [medline]
PHST- 2023/02/16 00:00 [pmc-release]
AID - 1112554 [pii]
AID - 10.3389/fphar.2023.1112554 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Feb 16;14:1112554. doi: 10.3389/fphar.2023.1112554. 
      eCollection 2023.